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Abstract: International experts recognize that significant inequities exist in the accessibility of life-saving medicines 
among poor and vulnerable populations, especially in developing countries. This article highlights that drug access even 
for relatively cheap medicines is out of reach for the vast numbers of global poor. This badly affects people living with 
HIV/AIDS who face serious obstacles in accessing ARVs. The same concerns are attributed to neglected diseases. Despite 
international meetings, promises from the pharmaceutical industry and a lot of media attention little has changed in the 
past 20 years. The accessibility gap to life-saving drugs could be reduced by the UNITAID initiative to pool patents for 
the many different ARVs, but the reality is that UNITAID is still a promise. To surmount this global problem of inequity 
requires a rethinking of traditional models of drug access and health objectives that should not be compromised by 
commercial interests. 
  Life saving and life-enhancing properties are the 
foundation of the moral and commercial significance of 
drugs. Pharmaceuticals are not ordinary “goods”. With about 
25 million persons living with HIV/AIDS still without access 
to needed drugs, the HIV/AIDS pandemic illuminated that 
access to life saving medicines is a basic human right, which 
is now becoming recognised worldwide. This is accepted 
internationally, for example, under the International 
Covenant on Economic, Social and Cultural Rights, in which 
Article 12 states that national governments have the 
responsibility to ensure and protect the right of their 
populations to the “highest attainable standard of physical 
and mental health” emphasizing health as an “inalienable 
and universal” human right. The UN Commission on Human 
Rights (2001) calls on States “to promote the right to health 
through access to affordable treatments and…(the) provision 
of essential drugs”. In spite of international appeal experts 
recognize that significant gaps exist in the agreement with 
respect to patent protection and access to as well as 
availability of life-saving medicines in developing countries. 
According to Gro Harlem Brundtland, former Director-
General of WHO (WHO, 2000): “At the beginning of the 
21
st Century, one-third of the world’s population still lacks 
access to the essential drugs it needs for good health. In the 
poorest parts of Africa and Asia, over 50% of the population 
do not have access to the most vital drugs”. 
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  The inefficient use of pharmaceutical resources in many 
developing countries also substantially reduces access to 
essential drugs and potential health benefits. Sometimes it is 
difficult to discern the difference between inefficiency and 
corruption. Governments in developing countries commonly 
lack adequate institutional capacity to regulate pharmaceu-
tical activities effectively. WHO reports that less than one in 
three regulatory agencies in developing countries works well 
and limited incentives for new drug development for 
diseases of developing countries reveal another market 
failure. 
  Drug access as noted above is critical. But so is drug 
availability. The issue of lags in research and development 
are not new. As Angell (2004) notes “The stream of new 
drugs has slowed to a trickle, and few of them are innovative 
in any sense of the word” [1]. Research and development 
(R&D) in the pharmaceutical industry is skewed; it largely 
does not invest in pharmaceuticals to treat tropical diseases. 
Of 1,223 new chemical entities (NCEs) commercialized 
from 1975-1990 379 were considered therapeutic 
innovations, and only 13 were specifically for tropical 
diseases (which comprise 10% of the world’s disease 
burden; and affect 65% of the world’s population). The 
common explanation for this is that the cost of R&D for 
them is prohibitive taking into account the low purchasing 
power of the poor countries, the presence of competition and 
counterfeit drugs, and the cost of adhering to quality 
standards [2]. 
  Despite international meetings focused on the issue, 
promises from the pharmaceutical industry and a lot of   
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media attention, little has changed in the past 20 years. 
Updating the NCEs data to 2004 reveals that, since 1990, 
among the 163 new NCEs only 4 NCEs were for neglected 
diseases (malaria and leishmaniasis) [3]. Developing 
countries represent a relatively small proportion of the global 
pharmaceutical market with only 20%, though they represent 
80% of world’s population. Most people in these countries 
must pay out of pocket for needed drugs and simply don’t 
have the resources to do so. This leads to limited market 
incentives for the development of new drugs specific to their 
diseases (including many tropical diseases). 
  Drug access, even for relatively cheap medicines, is out 
of reach for the vast numbers of global poor [4,5]. This 
relates particularly to people living with HIV/AIDS. An 
estimated 33 million people were living with HIV in 2007, 
and 1/3 of them also had TB. In response towards universal 
access and the scaling up priority of HIV/AIDS interventions 
in the health sector by WHO, UNAIDS, the Global Fund, 
PEPFAR and UNICEF (2008) nearly 3 million people are 
now receiving anti-retroviral therapy (ART) in low and 
middle income countries. However, this still represents only 
about 20% of those in need of these life saving drugs. And, 
there are more than 3 million new infections each year (and 
about 2.5 million deaths). 
  People living with HIV/AIDS in badly affected countries 
suffer from other obstacles in accessing their needed 
antiretroviral drugs (ARVs), including weak healthcare 
systems; lack of trained staff & “brain drain”, all of which 
calls strongly for the designing and implementation of task 
shifting (i.e., the shifting of responsibilities from higher 
trained personnel to lower trained ones, who can well handle 
the delegation); sustainable long-term financing; poor 
follow-up of babies born to HIV-positive mothers (in 2007, 
less than 4 per cent of such babies received proper treatment 
(Media Global, 2008); HIV and TB services are 
insufficiently integrated and too many people are losing their 
lives because they are unable to access life-saving 
medications for both diseases. It is best to integrate these 
services within the existing health care systems to strengthen 
them so that other desired targets can also be achieved. 
  As part of Millennium Development Goal #4 is to reduce 
child mortality with the target of reducing by two thirds the 
mortality rate among children under five by 2015, UNICEF 
reports that six million out of the eleven million children 
who die needlessly each year in developing countries could 
be saved by low-tech interventions, including access to 
essential medicines such as antibiotics. Ill-adapted and high 
cost drugs are challenges to children. Generally, most drugs 
currently available are not suited for use in resource-limited 
settings as they are either powders that need to be mixed 
with water or bitter-tasting syrups that also require 
refrigeration. According to Karen Day, pharmacist coordinator 
at Medecins Sans Frontieres’ (MSF) Campaign for Access to 
Essential Medicines: "So few children are born with HIV in 
developed countries that research into pediatric formulations 
is not a priority for pharmaceutical companies” [6]. A real 
challenge that treatment providers, including MSF, are 
facing is high prices for newer ARVs. People need to be able 
to have access to newer drugs to give them alternatives when 
they experience the side effects of their current drugs, or 
when they develop drug resistance. For these situations, they 
need access to new, more potent and less-toxic drugs. 
However, there is a serious price increase for a ‘second-line’ 
treatment regimens, from nine-fold to up to 17-fold in some 
middle-income countries where the drugs are patented and 
treatment providers must buy the product from the originator 
company. 
  The same concerns are attributed to neglected diseases, 
particularly infectious illnesses affecting developing countries 
that lack effective, affordable and easy to use drug treatments 
(e.g. malaria, tuberculosis, sleeping sickness). The public sector 
remains on the outside of drug development putting most of the 
critical decision making in the domain of the pharmaceutical 
industry, which prioritizes its R&D to marketable, profitable 
drugs (i.e. cancer, heart disease, depression, obesity, hair loss). 
Neglected diseases can be treated - but in most cases, treatments 
are antique (over 70 years old), becoming less effective, or non- 
existent. While neglected diseases do represent some kind of 
marketable profit (e.g. malaria, AIDS), most neglected diseases 
have no marketing opportunities or purchasing power and fall 
completely outside the pharmaceutical market [7]. This leads to 
the conclusion that we should not rely on the pharmaceutical 
industry to voluntarily invest in research and development for 
the neglected and most neglected diseases. 
  Accordingly, NGOs responding to the acute need have 
come forward to pressure key stakeholders, both in the 
government and industry. Some of these leading NGOs include: 
Global Treatment Action Group; People’s Health Movement; 
International Partners in Health; Essential-drugs.org; Third 
World Network; Global Forum for Health Research; and Drugs 
for Neglected Diseases Initiative (DNDi). Supportive initiatives 
also come from Medicines Sans Frontieres (MSF), an 
international humanitarian aid NGO, who in 2003 established 
DNDi. MSF formalized DNDi by uniting the work of five 
public sector institutions: Oswaldo Cruz Foundation (Brazil); 
Indian Council for Medical Research; Kenya Medical Research 
Institute; Ministry of Health of Malaysia; and Institute Pasteur 
(France). 
  DNDi brings together different players involved in clinical 
trials, treating neglected patients and enhancing the drug 
manufacturing capacities of developing countries [8]. DNDi 
currently focuses mainly on three neglected diseases. The first is 
sleeping sickness (Human African Trypanosomiasis) that 
infects 50,000 – 150,000 people yearly, is fatal if not treated and 
is localized only in sub-Saharan Africa. The second is Visceral 
Leishmaniasis (or Black Sickness/Kala-Azar) that affects over 
12 million people, and is located in over 80 particularly poor 
countries. The third is Chagas disease (another human form of 
trypanosomiasis) which is highly prevalent and localized in 
Latin America, and affects 8 million, mainly children. DNDi 
also focuses on malaria that presents in over 100 countries 
infecting 350- 500 million persons yearly, and causes over 1 
million deaths per year (3000 deaths per day). DNDi aims to 
have 6-7 drugs registered through its 12 year initiative by 2015. 
The cost of this initiative is over US$250 million, with the R&D 
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project drugs in the R&D stages and last year announced that, 
together with Sanofi-Aventis, they have developed a fixed-dose 
combination of two antimalarial compounds, artesunate and 
amodiaquine (AS/AQ). It is to be easier to use and more 
affordable than any other currently available combination. 
DNDi, itself, developed the formulation combining the two 
active ingredients into a single tablet and carried out the initial 
pharmaceutical and clinical development, before choosing 
Sanofi-Aventis as its industry partner for further development. 
  DNDi, though, cannot rely on market-based profit; rather it 
depends on public investment. Funding initially was provided 
by MSF, and current funders are: the European Union, 
international organizations, the general public and specialized 
private foundations. Bill and Melinda Gates Foundation, for 
example, provided US$25.7 million in 2007. In March 2008, 
DNDi announced a new two year collaboration with 
GlaxoSmithKline (GSK), focusing on R&D for three neglected 
diseases: sleeping sickness, Chagas disease and visceral 
leishmaniasis. Research will take place at GSK facilities in 
Spain. It is expected that further collaboration will be conducted 
with academic centers, including the London School of Hygiene 
& Tropical Medicine (LSHTM). 
  The gap in availability of life-saving drugs could be reduced 
by the UNITAID [9] initiative on pooling patents for the many 
different anti-retrovirals (ARVs). This could allow low- and 
middle-income countries to continue to access drugs at 
affordable prices and also facilitate the development of 
combination treatments and pediatric formulations. A patent 
pool is created when a number of patent rights, held by different 
owners (e.g., companies, universities, government institutions), 
are brought together (or pooled) and made available on a non-
exclusive basis. Such a scheme allows easier access to many 
patents and other intellectual properties and reduces risks and 
costs to companies. In February 2009, GSK announced it was 
making its technology patents for the control of many diseases 
available to such a pool. Patent pools make life saving 
medicines more widely available and affordable. UNITAID 
believes that this will greatly benefit children and people who 
have grown resistant to conventional AIDS therapy, for whom 
few fixed dose combination options currently exist [10,11]. But 
the reality is that UNITAID is still a promise and has yet to 
prove its value in helping to improve drug access. Moreover, the 
types of patents that are available in this pooling will be critical, 
because if the industry continues to keep patents closed in vital 
new therapies, we will achieve little. 
  Pharmaceutical access is vital to save lives. Health 
objectives should not be compromised by commercial 
objectives and political pressure from interest groups. Various 
organizations and individuals are trying to address the injustice 
of lack of access to life saving drugs. To overcome this requires 
a rethinking of traditional models and an honest appraisal of 
what partnerships mean and can achieve. 
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